Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B

When NICE recommends a treatment as an option for use with managed access, NHS England will make it available according to the conditions in the managed access agreement. This means that, if a patient has moderately severe or severe haemophilia B and the healthcare professional responsible for their care thinks that etranacogene dezaparvovec is the right treatment, it should be available for use, in line with NICE's recommendations and the criteria in the managed access agreement. Further information can be found in the Innovative Medicines Fund principles.

Interim funding for etranacogene dezaparvovec will be available through the Innovative Medicines Fund when positive final draft guidance is released.

The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance when the drug or treatment, or other technology, is approved for use with managed access. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, for use with managed access, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final draft guidance or agreement of a managed access agreement by the NHS in Wales, whichever is the later.